10-Q: Humana Q3 Profit Plunges Amid Strategic Restructuring

Humana Inc. reported a significant 59.4% drop in third-quarter net income to $195 million, primarily due to substantial charges from value creation initiatives and a business divestiture, despite robust revenue growth.

Summary

• Net income attributable to Humana for the three months ended September 30, 2025, was $195 million, a decrease from $480 million in the prior-year quarter.
• Diluted earnings per common share for Q3 2025 were $1.62, down from $3.98 in Q3 2024.
• Total revenues increased 11.1% to $32.6 billion for the three months ended September 30, 2025, driven by higher premiums and services revenue.
• The benefit ratio increased to 91.1% in Q3 2025 from 89.9% in Q3 2024, reflecting a shift in business mix and incremental investments.
• Operating costs rose 22.3% to $4.1 billion in Q3 2025, impacted by charges from value creation initiatives and business mix changes.
• For the nine months ended September 30, 2025, net income attributable to Humana increased to $1.98 billion from $1.90 billion in the prior-year period, with diluted EPS rising to $16.43 from $15.72.
• Individual Medicare Advantage membership decreased by 7.5% to 5,237,300 members, due to the decision to exit certain unprofitable plans and counties.
• Medicare stand-alone PDP membership increased by 5.6% to 2,446,200 members, and state-based contracts membership grew by 14.7% to 1,658,800 members.
• Cash and cash equivalents increased to $5.4 billion at September 30, 2025, from $2.2 billion at December 31, 2024.
• The U.S. District Court for the Northern District of Texas granted Humana's motion for summary judgment and vacated the Final RADV Rule on September 25, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant decline in Q3 net income and EPS, driven by substantial one-time charges and a loss on sale of business. While year-to-date results show modest growth and revenues are strong, the short-term profitability hit, ongoing legal challenges (despite a win on RADV, the Star Ratings challenge was rejected, and a new DOJ lawsuit emerged), and membership decline in a key segment (Individual MA) create considerable headwinds and uncertainty. The 'value creation initiatives' are costly in the short term, even if intended for long-term benefit.

Positives

• Total revenues increased by 11.1% for the three months and 9.7% for the nine months ended September 30, 2025, demonstrating strong top-line growth.
• Services revenue saw significant growth, up 45.1% for the quarter and 32.7% for the nine months, primarily from primary care and pharmacy solutions businesses.
• Net income attributable to Humana for the nine months ended September 30, 2025, increased by 4.4% to $1.98 billion, indicating overall year-to-date profitability improvement.
• Diluted earnings per common share for the nine months ended September 30, 2025, increased by 4.5% to $16.43.
• Cash and cash equivalents significantly increased to $5.4 billion at September 30, 2025, from $2.2 billion at December 31, 2024, reflecting strong liquidity.
• Net cash provided by investing activities improved substantially to $1.64 billion for the nine months ended September 30, 2025, compared to a net use of $2.89 billion in the prior year.
• The U.S. District Court granted Humana's motion for summary judgment and vacated the Final RADV Rule on September 25, 2025, a favorable outcome in a significant legal challenge.
• Membership growth was observed in Group Medicare Advantage (+4.2%), Medicare stand-alone PDP (+5.6%), and state-based contracts (+14.7%).
• Administrative cost efficiencies are resulting from value creation initiatives, partially offsetting the impact of related charges.

Negatives

• Net income attributable to Humana for the three months ended September 30, 2025, decreased by 59.4% to $195 million, significantly impacted by one-time charges.
• Diluted earnings per common share for the three months ended September 30, 2025, decreased by 59.3% to $1.62.
• Income from operations decreased by 45.1% for the three months ended September 30, 2025, to $400 million.
• The consolidated benefit ratio increased by 120 basis points to 91.1% for the three months ended September 30, 2025, indicating lower underwriting profitability.
• The consolidated operating cost ratio increased by 110 basis points to 12.6% for the three months ended September 30, 2025, due to business mix changes and value creation initiative charges.
• Individual Medicare Advantage membership declined by 7.5% (421,900 members) due to the decision to exit certain unprofitable plans and counties.
• Military services membership decreased by 23.0% (1,379,400 members).
• A loss on sale of business of $63 million was recorded for the three and nine months ended September 30, 2025.
• Significant charges of $267 million (Q3 2025) and $320 million (9M 2025) were incurred for value creation initiatives, primarily severance and external consulting spend.
• The U.S. District Court rejected Humana's challenge to the 2025 Star Ratings on October 14, 2025, and the company is considering its options.
• A DOJ complaint in partial intervention was filed on May 1, 2025, alleging civil violations related to non-commission payments to brokers and marketing practices.

Risks

• The Final RADV Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, the expansion of CMS's auditing efforts to include all eligible MA contracts, the acceleration of RADV audits for PY 2018 through PY 2024, other changes CMS may make to the RADV audit methodology for these years, and combination of these expanded auditing efforts with the application of the Final RADV Rule, could each have a material adverse effect on results of operations, financial position, or cash flows.
• The outcome of the lawsuit challenging the Final RADV Rule cannot be assured, despite the recent summary judgment in Humana's favor.
• Internal compliance reviews of risk coding and data submissions may identify errors and require corrections to CMS, potentially having a material adverse effect.
• Loss of government contracts (Medicare, Medicaid) or significant changes in these programs (e.g., reductions in premium payments, regulatory restrictions on profitability, increases in member benefits without corresponding premium increases) may materially adversely affect results.
• Ongoing legal proceedings, including the putative stockholder class action and parallel stockholder derivative actions related to alleged false or misleading statements about financial performance, medical costs, and Star Ratings, could result in substantial judgments, penalties, or fines.
• The DOJ qui tam lawsuit alleging civil violations in connection with non-commission payments to brokers and marketing of Medicare Advantage plans could lead to damages and penalties under the federal False Claims Act.
• Other lawsuits and regulatory matters, including those related to claims payment practices, statutory capital requirements, provider contracting, and privacy issues, could result in additional fines, sanctions, or changes in business practices.
• Adverse changes in credit ratings may increase interest rates on debt and impact the availability of future credit.
• The parent company is dependent on dividends and administrative expense reimbursements from subsidiaries, which are subject to regulatory restrictions and minimum capital requirements.

Future Outlook

The company expects to incur additional charges in 2025 related to its value creation initiatives. Changes to the Medicare Part D benefit design, effective January 1, 2025, are anticipated to reduce out-of-pocket costs for beneficiaries and result in more level net prescription costs throughout the year. The company's integrated care delivery model is positioned for long-term growth in both membership and earnings. The company believes its current liquidity resources are adequate to fund ongoing operating and regulatory requirements, acquisitions, future expansion, capital expenditures, and debt refinancing for at least the next twelve months.

Management Comments

• Committed to putting health first for teammates, customers, and the company.
• Making it easier for millions of people served to achieve their best health, delivering care and service when needed.
• Efforts are leading to a better quality of life for Medicare and Medicaid participants, families, individuals, military service personnel, and communities at large.
• Committed to driving additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments to fund growth and investment in the Medicare Advantage business and further expansion of healthcare services capabilities.
• Believe the integrated care delivery model is positioning the company for long-term growth in both membership and earnings.
• Vigorously defending against allegations in all legal cases, including the stockholder class action and derivative actions.
• Committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for members.

Industry Context

The healthcare industry, particularly the Medicare Advantage and Part D sectors, is undergoing significant regulatory and competitive changes. The Inflation Reduction Act of 2022 (IRA) has fundamentally altered the Medicare Part D benefit design, eliminating the coverage gap and capping beneficiary out-of-pocket expenses, which impacts plan liabilities and seasonality of costs. The Centers for Medicare and Medicaid Services (CMS) continues to intensify its auditing efforts, including RADV audits, creating a challenging regulatory environment for MA plans. Humana's strategic decision to exit unprofitable individual Medicare Advantage plans reflects a broader industry trend of optimizing portfolios in response to evolving market dynamics and regulatory pressures. The company's focus on value creation initiatives and expansion of its CenterWell healthcare services aligns with a trend towards integrated care delivery models aimed at improving outcomes and cost-effectiveness.

Comparison to Industry Standards

• The increase in the consolidated benefit ratio to 91.1% for Q3 2025, compared to 89.9% in Q3 2024, suggests a potential divergence from industry peers that may be experiencing more stable or improving underwriting profitability, especially given the company's 'incremental investments to improve member and patient outcomes and support operational excellence.'
• The decline in individual Medicare Advantage membership by 7.5% contrasts with some competitors who may be maintaining or growing their MA enrollment, indicating Humana's specific strategic decision to exit 'unprofitable plans and counties' rather than a universal industry contraction.
• The significant charges related to 'value creation initiatives' ($267 million in Q3 2025) highlight a substantial internal restructuring effort, which may be more aggressive or extensive than similar efficiency programs undertaken by other large health insurers in the same period.
• The successful vacating of the Final RADV Rule by the U.S. District Court on September 25, 2025, represents a significant legal victory for Humana, potentially differentiating its legal standing on this specific regulatory issue compared to other MA plans that may not have pursued or achieved similar outcomes.
• The rejection of Humana's challenge to the 2025 Star Ratings on October 14, 2025, places it in a similar position to other MA plans that have faced challenges with CMS's Star Ratings methodology, indicating ongoing industry-wide friction with regulatory assessment mechanisms.

Corporate Governance

Legal Proceedings

• On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. On September 25, 2025, the Court granted Humana's motion for summary judgment and vacated the Final RADV Rule, finding it procedurally invalid.
• In June 2024, a putative stockholder class action was filed against Humana Inc. and certain current and former executive officers, alleging false or misleading statements in SEC filings and to financial markets about financial performance, medical costs, and Star Ratings between July 2022 and October 2024.
• Between July 2024 and March 2025, parallel stockholder derivative actions were filed, alleging breach of fiduciary duty by certain current and former directors and executive officers based on the same claimed acts and omissions as the federal securities law case.
• On October 18, 2024, Humana Inc., along with co-plaintiff Americans for Beneficiary Choice, filed suit against the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, and officials, challenging the Medicare Advantage and Part D Star Ratings program. The case was dismissed on July 18, 2025, for failure to exhaust administrative remedies, refiled on July 21, 2025, and the Court rejected the challenge to the 2025 Star Ratings on October 14, 2025.
• On May 1, 2025, the Department of Justice (DOJ) filed a complaint in partial intervention related to a qui tam lawsuit, alleging civil violations in connection with non-commission payments Humana made to three call center broker partners and marketing of Medicare Advantage plans to Medicare-eligible beneficiaries under the age of 65.

Stakeholder Impact

• Shareholders: Experienced a significant decline in Q3 diluted EPS, but year-to-date EPS showed modest growth. The share repurchase program and consistent dividends aim to return value. Legal uncertainties and strategic restructuring could impact future share price volatility.
• Employees: Impacted by 'workforce optimization' as part of value creation initiatives, leading to severance charges.
• Customers (Medicare/Medicaid members): Medicare Part D changes (IRA) are anticipated to reduce out-of-pocket costs for beneficiaries. The integrated care delivery model aims to improve health outcomes and affordability. Exiting unprofitable MA plans may affect some members' plan choices.
• Providers: The company relies on providers for diagnosis data submission for risk adjustment. The RADV audit lawsuit outcome could influence future payment methodologies and provider compliance requirements.
• Creditors: The company maintains investment-grade credit ratings (BBB by S&P, Baa2 by Moody's) and is in compliance with debt covenants, indicating a stable credit profile despite increased debt issuance.

Next Steps

• Incur additional charges related to value creation initiatives in 2025.
• Continue to work alongside CMS to promote the integrity of the MA program and affordability for members.
• Consider options regarding the court's decision rejecting the challenge to the 2025 Star Ratings.
• Vigorously defend against allegations in the DOJ qui tam lawsuit and other legal proceedings.
• The Board declared a cash dividend of $0.885 per share payable on January 30, 2026, to stockholders of record as of December 26, 2025.
• CMS intends to extrapolate results from RADV audits beginning with PY 2018 and expedite completion of RADV audits for PY 2018 through PY 2024 by early 2026.

Key Dates

Recommendation

Humana's Q3 2025 results show a substantial decline in net income and EPS, primarily due to significant one-time charges from value creation initiatives and a business divestiture. While year-to-date performance is modestly positive and revenue growth remains strong, these short-term impacts, coupled with ongoing legal challenges (despite a favorable RADV ruling, the Star Ratings challenge was rejected, and a new DOJ lawsuit has emerged), create a complex investment landscape. The company is undergoing strategic restructuring, including exiting unprofitable Medicare Advantage plans, which is intended for long-term benefit but creates near-term volatility. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of the value creation initiatives, the resolution of legal proceedings, and the impact of Medicare Part D changes on future profitability and membership trends before making further investment decisions.

Keywords

Humana, 10-Q, Quarterly Report, Medicare Advantage, Healthcare Services, Financial Results, Earnings, Revenue, Profitability, SEC Filing, Value Creation Initiatives, RADV Audit, Star Ratings, Legal Proceedings, Membership, Insurance, CenterWell, IRA, Inflation Reduction Act, Debt, Cash Flow